EDAP TMS SA, the global leader in therapeutic ultrasound, today announced the first installation of Ablatherm Robotic HIFU at University of Southern California, Keck Medicine of USC, which will become the first reference and training center for Ablatherm Robotic HIFU in the U.S.
Dr. Inderbir Gill, M.D., Professor & Chairman, USC Institute of Urology at Keck Medicine of the University of Southern California (USC) in Los Angeles, commented: "FDA clearance of HIFU is a tremendous milestone for the urology community. We are delighted to be the first in the U.S. to treat patients on a routine basis with the Ablatherm Robotic HIFU, on December 10 and 11, 2015. We look forward to helping appropriate patients using this groundbreaking technology, thus opening new options and horizons for prostate ablation procedures."
Marc Oczachowski, EDAP TMS Chief Executive Officer, added: 'We are thrilled to have the first installation of Ablatherm Robotic HIFU following FDA clearance at such a prestigious university hospital as USC Keck Medical Center, which was one of the first facilities to purchase the device in the U.S. It is an honor to be working with the world class urology team led by Dr. Inderbir Gill, one of the top urologists in the world, and to collaborate with them on the establishment of a state-of-the-art training and reference center for Ablatherm Robotic HIFU in the U.S."
About EDAP TMS SA
EDAP TMS SA markets today Ablatherm® for high-intensity focused ultrasound (HIFU) for prostate tissue ablation in the U.S. and for treatment of localized prostate cancer in the rest of the world. HIFU treatment is shown to be a minimally invasive and effective option for prostatic tissue ablation with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Ablatherm-HIFU is approved for commercial distribution in Europe and some other countries including Mexico and Canada, and has received 510(k) clearance by the U.S. FDA. The Company also markets an innovative robot-assisted HIFU device, the Focal One®, dedicated to focal therapy of prostate cancer. Focal One® is CE marked but is not FDA approved. The Company also develops its HIFU technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and distributes medical equipment (the Sonolith® lithotripters' range) for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL) in most countries including Canada and the U.S. For more information on the Company, please visit http://www.edap-tms.com, and http://www.hifu-planet.com.